Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.44 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | STAT3 | P40763 | 2/20 | 0.39 |
| ▸ | MPL | P40238 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.39 |
| ▸ | DEGS1 | O15121 | 2/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18094571 | 0.91 | LRRK2 (0.46) | LRRK2MAPTSTAT3MPLSMN1; SMN2 | |
| SCHEMBL18094563 | 0.90 | LRRK2 (0.45) | LRRK2MAPTSTAT3MPLSMN1; SMN2 | |
| SCHEMBL18094547 | 0.89 | LRRK2 (0.57) | LRRK2MAPTSTAT3SMN1; SMN2 | |
| SCHEMBL18094555 | 0.89 | SMN1; SMN2 (0.52) | LRRK2MAPTKCNH2STAT3SMN1; SMN2 | |
| SCHEMBL18094531 | 0.88 | DEGS1 (0.44) | LRRK2MAPTSTAT3MPLSMN1; SMN2 | |
| SCHEMBL18094509 | 0.83 | GPR119 (0.47) | LRRK2MAPTSMN1; SMN2 | |
| SCHEMBL18094484 | 0.82 | PTGS1 (0.51) | MAPTSTAT3MPLDEGS1MCHR1 | |
| SCHEMBL18094536 | 0.82 | MAPT (0.44) | MAOBMAPTBRAFSTAT3MPL | |
| SCHEMBL18094515 | 0.81 | ADORA3 (0.48) | LRRK2MAPKAPK2 | |
| SCHEMBL16718785 | 0.80 | LMNA (0.53) | MAPTSTAT3MPLDEGS1PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170202849-A1 | ANTIPARASITIC COMPOUNDS | AVISTA PHARMA SOLUTIONS, INC. | 2017-07-20 | — | — | US | claimed |
| US-9643963-B2 | Antiparasitic compounds | AVISTA PHARMA SOLUTIONS, INC. (US) | 2017-05-09 | — | — | US | claimed |
| US-20160280700-A1 | ANTIPARASITIC COMPOUNDS | SNAPDRAGON CHEMISTRY, INC. | 2016-09-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280700-A1 | ANTIPARASITIC COMPOUNDS | TPP2, TPP1, SERPINB1 | MAOB 788/4885LRRK2 3698/4885MAPKAPK2 3641/4885 |
| US-20170202849-A1 | ANTIPARASITIC COMPOUNDS | TPP2, TPP1, SERPINB1 | MAOB 788/4885LRRK2 3698/4885MAPKAPK2 3641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.